132 related articles for article (PubMed ID: 3509064)
1. Effects of debrisoquin and haloperidol on plasma homovanillic acid concentration in schizophrenic patients.
Davidson M; Losonczy MF; Mohs RC; Lesser JC; Powchik P; Freed LB; Davis BM; Mykytyn VV; Davis KL
Neuropsychopharmacology; 1987 Dec; 1(1):17-23. PubMed ID: 3509064
[TBL] [Abstract][Full Text] [Related]
2. Effects of debrisoquin on plasma homovanillic acid concentration in schizophrenic patients.
Davidson M; Losonczy MF; Mohs RC; Powchick P; Freed LB; Kaminsky R; Davis KL
Psychopharmacol Bull; 1987; 23(3):407-10. PubMed ID: 3432512
[No Abstract] [Full Text] [Related]
3. Plasma debrisoquin levels in the assessment of reduction of plasma homovanillic acid. The debrisoquin method.
Riddle MA; Jatlow PI; Anderson GM; Cho SC; Hardin MT; Cohen DJ; Leckman JF
Neuropsychopharmacology; 1989 Jun; 2(2):123-9. PubMed ID: 2742727
[TBL] [Abstract][Full Text] [Related]
4. Assessment of central dopaminergic function using plasma-free homovanillic acid after debrisoquin administration.
Riddle MA; Leckman JF; Cohen DJ; Anderson M; Ort SI; Caruso KA; Shaywitz BA
J Neural Transm; 1986; 67(1-2):31-43. PubMed ID: 3465864
[TBL] [Abstract][Full Text] [Related]
5. Acute effects of neuroleptics on unmedicated schizophrenic patients and controls.
Miller AL; Maas JW; Contreras S; Seleshi E; True JE; Bowden C; Castiglioni J
Biol Psychiatry; 1993 Aug; 34(3):178-87. PubMed ID: 8104509
[TBL] [Abstract][Full Text] [Related]
6. Plasma homovanillic acid as an index of brain dopamine metabolism: enhancement with debrisoquin.
Sternberg DE; Heninger GR; Roth RH
Life Sci; 1983 May; 32(21):2447-52. PubMed ID: 6855448
[TBL] [Abstract][Full Text] [Related]
7. Increase in human urine homovanillic acid concentration after neuroleptic treatment is the same with or without debrisoquin administration.
Contreras SA; Maas JW; Seleshi E; Bowden CL
Arch Gen Psychiatry; 1987 Dec; 44(12):1109-10. PubMed ID: 3689099
[No Abstract] [Full Text] [Related]
8. Effects of neuroleptic treatment on symptoms of schizophrenia and plasma homovanillic acid concentrations.
Davidson M; Kahn RS; Knott P; Kaminsky R; Cooper M; DuMont K; Apter S; Davis KL
Arch Gen Psychiatry; 1991 Oct; 48(10):910-3. PubMed ID: 1929760
[TBL] [Abstract][Full Text] [Related]
9. Brief debrisoquin administration to assess central dopaminergic function in children.
Riddle MA; Shaywitz BA; Leckman JF; Anderson GM; Shaywitz SE; Hardin MT; Ort SI; Cohen DJ
Life Sci; 1986 Mar; 38(11):1041-8. PubMed ID: 3456480
[TBL] [Abstract][Full Text] [Related]
10. Plasma catecholamine metabolites in schizophrenics: evidence for the two-subtype concept.
Chang WH; Chen TY; Lin SK; Lung FW; Lin WL; Hu WH; Yeh EK
Biol Psychiatry; 1990 Mar; 27(5):510-8. PubMed ID: 2310806
[TBL] [Abstract][Full Text] [Related]
11. Assessment of dopaminergic function in children and adults: long and brief debrisoquin administration combined with plasma homovanillic acid.
Riddle MA; Leckman JF; Anderson GM; Hardin MT; Ort SI; Towbin KE; Shaywitz BA; Cohen DJ
Psychopharmacol Bull; 1987; 23(3):411-4. PubMed ID: 3481088
[No Abstract] [Full Text] [Related]
12. Evolution of plasma homovanillic acid (HVA) in chronic schizophrenic patients treated with haloperidol.
Galinowski A; Poirier MF; Aymard N; Leyris A; Beauverie P; Bourdel MC; Loo H
Acta Psychiatr Scand; 1998 Jun; 97(6):458-66. PubMed ID: 9669519
[TBL] [Abstract][Full Text] [Related]
13. The acute effects of central- and peripheral-acting dopamine antagonists on plasma HVA in schizophrenic patients.
Konicki PE; Owen RR; Litman RE; Pickar D
Life Sci; 1991; 48(14):1411-6. PubMed ID: 2008157
[TBL] [Abstract][Full Text] [Related]
14. Plasma prolactin and homovanillic acid as markers for psychopathology and abnormal movements after neuroleptic dose decrease.
Newcomer JW; Riney SJ; Vinogradov S; Csernansky JG
Psychopharmacol Bull; 1992; 28(1):101-7. PubMed ID: 1609034
[TBL] [Abstract][Full Text] [Related]
15. Plasma homovanillic acid and treatment response in a large group of schizophrenic patients.
Chang WH; Hwu HG; Chen TY; Lin SK; Lung FW; Chen H; Lin WL; Hu WH; Lin HN; Chien CP
Schizophr Res; 1993 Oct; 10(3):259-65. PubMed ID: 8260444
[TBL] [Abstract][Full Text] [Related]
16. Brain contribution to the haloperidol-induced increase in plasma homovanillic acid.
Kendler KS; Heninger GR; Roth RH
Eur J Pharmacol; 1981 May; 71(2-3):321-6. PubMed ID: 7250191
[TBL] [Abstract][Full Text] [Related]
17. Negative symptoms in nondeficit syndrome respond to neuroleptic treatment with changes in plasma homovanillic acid concentrations.
Suzuki E; Kanba S; Koshikawa H; Nibuya M; Yagi G; Asai M
J Psychiatry Neurosci; 1996 May; 21(3):167-71. PubMed ID: 8935328
[TBL] [Abstract][Full Text] [Related]
18. Apomorphine has no effect on plasma homovanillic acid in schizophrenic patients.
Davidson M; Kendler KS; Davis BM; Horvath TB; Mohs RC; Davis KL
Psychiatry Res; 1985 Oct; 16(2):95-9. PubMed ID: 3865258
[TBL] [Abstract][Full Text] [Related]
19. Haloperidol response and plasma catecholamines and their metabolites.
Green AI; Alam MY; Boshes RA; Waternaux C; Pappalardo KM; Fitzgibbon ME; Tsuang MT; Schildkraut JJ
Schizophr Res; 1993 Jun; 10(1):33-7. PubMed ID: 8369230
[TBL] [Abstract][Full Text] [Related]
20. Plasma homovanillic acid as a predictor of response to neuroleptics.
Davila R; Manero E; Zumarraga M; Andia I; Schweitzer JW; Friedhoff AJ
Arch Gen Psychiatry; 1988 Jun; 45(6):564-7. PubMed ID: 3377643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
